Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OraSure Technologies, Inc. (NASDAQ: OSUR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a public medical devices issuer, OraSure files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its financial condition, operating performance, and significant corporate events.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and related investor communications. For example, OraSure has furnished press releases announcing consolidated financial results for quarters ended June 30 and September 30, along with investor presentations and details of webcast conference calls with analysts and investors. Other 8-K filings document changes in the composition of the board of directors, such as the resignation of a board chair, the appointment of a new chair, and the addition of an independent director, including information about committee assignments and director compensation under the company’s non-employee director compensation policy.
Through its periodic reports, OraSure provides segment and category-level revenue information across diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product and services revenues. These filings also discuss operating expenses, cash and cash equivalents, capital expenditures, and other financial metrics, as well as risk factors and forward-looking statements related to regulatory approvals, customer demand, competition, funding for public health programs, and broader economic conditions.
On this page, Stock Titan’s tools surface real-time updates from EDGAR and apply AI-generated highlights to key sections of OraSure’s filings, helping users quickly identify items such as quarterly performance trends, changes in governance, and material events disclosed in 8-Ks. Users can also review information related to equity awards and director compensation as described in proxy statements and referenced in current reports. Together, these resources offer a structured view of OSUR’s regulatory history and ongoing disclosure obligations.
OraSure Technologies Inc: Amendment No. 10 to a Schedule 13G/A discloses that The Vanguard Group reports 0 shares beneficially owned and 0% of the common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report disaggregated ownership separately in reliance on SEC Release No. 34-39538.
The form lists Vanguard's address and notes the filing was signed by Ashley Grim, Head of Global Fund Administration on 03/27/2026. The filing classifies this holding as ownership of 5 percent or less.
OraSure Technologies Chief Financial Officer Kenneth J. McGrath reported an open-market purchase of 32,300 shares of common stock. The trade occurred on March 20, 2026 at a weighted average price of $2.9288 per share, with individual prices ranging from $2.86 to $2.98.
After this transaction, McGrath directly holds 589,562 OraSure shares. The purchase was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on November 28, 2025, indicating the buying activity was scheduled in advance rather than timed discretionarily.
OraSure Technologies President & CEO Carrie Eglinton-Manner bought 32,300 shares of common stock in an open-market transaction. The shares were purchased on March 20, 2026 at a weighted average price of $2.9287 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025.
After this purchase, she directly owns 2,190,874 OraSure shares. The filing notes the shares were acquired through multiple trades within a price range of $2.86 to $2.98 per share.
OraSure Technologies senior vice president of finance and chief accounting officer Anthony Michele Marie reported routine equity compensation activity in common stock. On March 2, 2026, she received a grant of 42,982 shares of restricted stock that vest in three equal annual installments beginning on March 2, 2027, contingent on continued service.
On March 1, 2026, she acquired 14,183 shares in settlement of vested performance units, then had 4,062 shares and 10,817 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly held 185,788 shares of OraSure common stock.
OraSure Technologies received an amended Schedule 13D from Altai Capital, led by Rishi Bajaj, reflecting an activist position. The reporting persons beneficially own 3,613,836 shares of common stock, representing 5.2% of the company based on 69,126,173 shares outstanding as of February 28, 2026.
On March 17, 2026, Altai Capital’s investment manager issued a press release with an open letter to the board outlining its case for change and reiterating its intention to solicit proxies to elect Rishi Bajaj and John Bertrand at the annual meeting. The full letter is filed as Exhibit 99.3.
OraSure Technologies received an amended Schedule 13D from Altai Capital, led by Rishi Bajaj, reflecting an activist position. The reporting persons beneficially own 3,613,836 shares of common stock, representing 5.2% of the company based on 69,126,173 shares outstanding as of February 28, 2026.
On March 17, 2026, Altai Capital’s investment manager issued a press release with an open letter to the board outlining its case for change and reiterating its intention to solicit proxies to elect Rishi Bajaj and John Bertrand at the annual meeting. The full letter is filed as Exhibit 99.3.
Altai Capital, a shareholder owning approximately 5% of OraSure Technologies (OSUR), has filed a Schedule 14A nominating Rishi Bajaj and John Bertrand for the 2026 Annual Meeting and delivered a letter urging board change. Altai cites chronic underperformance (stock declines of 67% and 56% on 5- and 10-year bases as of 03/06/26), management compensation misalignment (an estimated $15 million earned by the CEO over her tenure), and capital allocation decisions including a $30 million investment in Sapphiros and a Sherlock Biosciences acquisition with contingent payments.
Altai requests a strategic review including consideration of a sale, seeks board seats for its nominees, and says it will solicit votes if no settlement is reached.
Altai Capital, a shareholder owning approximately 5% of OraSure Technologies (OSUR), has filed a Schedule 14A nominating Rishi Bajaj and John Bertrand for the 2026 Annual Meeting and delivered a letter urging board change. Altai cites chronic underperformance (stock declines of 67% and 56% on 5- and 10-year bases as of 03/06/26), management compensation misalignment (an estimated $15 million earned by the CEO over her tenure), and capital allocation decisions including a $30 million investment in Sapphiros and a Sherlock Biosciences acquisition with contingent payments.
Altai requests a strategic review including consideration of a sale, seeks board seats for its nominees, and says it will solicit votes if no settlement is reached.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported an open-market purchase of 22,021 shares of common stock. The shares were bought on March 13, 2026 at a weighted average price of $2.9985 per share, in multiple trades between $2.93 and $3.12. Following this transaction, he directly owns 557,262 shares. The purchase was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2025.
OraSure Technologies President & CEO Carrie Eglinton Manner purchased 22,022 shares of common stock in an open-market transaction at a weighted average price of $2.9985 per share.
The trade was executed under a pre-arranged Rule 10b5-1 trading plan, and following this purchase she directly owns 2,158,574 OraSure shares.
OraSure Technologies, Inc. details its diagnostics and sample management business in an annual report for the year ended December 31, 2025. The company develops rapid tests for HIV, hepatitis C, syphilis, Ebola, sickle cell and COVID-19, plus saliva, urine and microbiome collection systems sold globally to clinical, research and commercial customers.
In November 2025 OraSure acquired BioMedomics, adding the SickleSCAN rapid sickle cell test sold outside the U.S. The company is advancing new products, including a rapid molecular self-test for chlamydia and gonorrhea and an at-home Colli-Pee urine collection device for sexually transmitted infections, both with 510(k) submissions filed in December 2025 and under FDA review.
Revenue mix is shifting sharply as InteliSwab COVID-19 test sales fell from $257,493,000 in 2023 to $45,136,000 in 2024 and $620,000 in 2025, while OraQuick HIV revenue declined to $49,802,000 in 2025 and Genomics products to $31,546,000. A single non-commercial customer represented 63% of revenue in 2023, 24% in 2024 and about 3% in 2025, highlighting reduced concentration but significantly lower COVID-related volumes.
OraSure exited its substance abuse testing business, continues to invest in BARDA-supported Ebola and Marburg virus tests, and emphasizes intellectual property protection across its brands and collection technologies. As of December 31, 2025, the company employed 500 people and held an aggregate non‑affiliate market value of $218,472,693 as of June 30, 2025, with 69,126,173 common shares outstanding as of February 28, 2026.
OraSure Technologies, Inc. reported a change on its board of directors. On February 28, 2026, director David J. Shulkin, M.D. informed the board that he will resign as a director, including his role on the Compensation Committee, effective March 2, 2026.
The company stated that Dr. Shulkin’s decision to step down is not due to any dispute or disagreement with the board, the company, or its management. The board expressed its appreciation for his years of service and contributions. The filing was signed by President and Chief Executive Officer Carrie Eglinton Manner.